The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Durvalumab Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2028
Synopsis
The Durvalumab market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Durvalumab market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Locally Advanced Urothelial Carcinoma accounting for % of the Durvalumab global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While 2.4mL Injection segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Durvalumab include Medimmune (AstraZeneca), , , , and , etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Durvalumab market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
2.4mL Injection
10mL Injection
Market segment by Application can be divided into
Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Other
The key market players for global Durvalumab market are listed below:
Medimmune (AstraZeneca)
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Durvalumab product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Durvalumab, with price, sales, revenue and global market share of Durvalumab from 2019 to 2022.
Chapter 3, the Durvalumab competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Durvalumab breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Durvalumab market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Durvalumab.
Chapter 13, 14, and 15, to describe Durvalumab sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Geographical Area
Global
The Durvalumab market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Durvalumab market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Locally Advanced Urothelial Carcinoma accounting for % of the Durvalumab global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While 2.4mL Injection segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Durvalumab include Medimmune (AstraZeneca), , , , and , etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Durvalumab market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
2.4mL Injection
10mL Injection
Market segment by Application can be divided into
Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Other
The key market players for global Durvalumab market are listed below:
Medimmune (AstraZeneca)
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Durvalumab product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Durvalumab, with price, sales, revenue and global market share of Durvalumab from 2019 to 2022.
Chapter 3, the Durvalumab competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Durvalumab breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Durvalumab market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Durvalumab.
Chapter 13, 14, and 15, to describe Durvalumab sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Geographical Area
Global
Index1 Market Overview
1.1 Durvalumab Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Durvalumab Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 2.4mL Injection
1.2.3 10mL Injection
1.3 Market Analysis by Application
1.3.1 Overview: Global Durvalumab Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Locally Advanced Urothelial Carcinoma
1.3.3 Metastatic Urothelial Carcinoma
1.3.4 Other
1.4 Global Durvalumab Market Size & Forecast
1.4.1 Global Durvalumab Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Durvalumab Sales in Volume (2017-2028)
1.4.3 Global Durvalumab Price (2017-2028)
1.5 Global Durvalumab Production Capacity Analysis
1.5.1 Global Durvalumab Total Production Capacity (2017-2028)
1.5.2 Global Durvalumab Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Durvalumab Market Drivers
1.6.2 Durvalumab Market Restraints
1.6.3 Durvalumab Trends Analysis
2 Manufacturers Profiles
2.1 Medimmune (AstraZeneca)
2.1.1 Medimmune (AstraZeneca) Details
2.1.2 Medimmune (AstraZeneca) Major Business
2.1.3 Medimmune (AstraZeneca) Durvalumab Product and Services
2.1.4 Medimmune (AstraZeneca) Durvalumab Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Durvalumab Breakdown Data by Manufacturer
3.1 Global Durvalumab Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Durvalumab Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Durvalumab
3.4 Market Concentration Rate
3.4.1 Top 3 Durvalumab Manufacturer Market Share in 2021
3.4.2 Top 6 Durvalumab Manufacturer Market Share in 2021
3.5 Global Durvalumab Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Durvalumab Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Durvalumab Market Size by Region
4.1.1 Global Durvalumab Sales in Volume by Region (2017-2028)
4.1.2 Global Durvalumab Revenue by Region (2017-2028)
4.2 North America Durvalumab Revenue (2017-2028)
4.3 Europe Durvalumab Revenue (2017-2028)
4.4 Asia-Pacific Durvalumab Revenue (2017-2028)
4.5 South America Durvalumab Revenue (2017-2028)
4.6 Middle East and Africa Durvalumab Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Durvalumab Sales in Volume by Type (2017-2028)
5.2 Global Durvalumab Revenue by Type (2017-2028)
5.3 Global Durvalumab Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Durvalumab Sales in Volume by Application (2017-2028)
6.2 Global Durvalumab Revenue by Application (2017-2028)
6.3 Global Durvalumab Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Durvalumab Sales by Type (2017-2028)
7.2 North America Durvalumab Sales by Application (2017-2028)
7.3 North America Durvalumab Market Size by Country
7.3.1 North America Durvalumab Sales in Volume by Country (2017-2028)
7.3.2 North America Durvalumab Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Durvalumab Sales by Type (2017-2028)
8.2 Europe Durvalumab Sales by Application (2017-2028)
8.3 Europe Durvalumab Market Size by Country
8.3.1 Europe Durvalumab Sales in Volume by Country (2017-2028)
8.3.2 Europe Durvalumab Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Durvalumab Sales by Type (2017-2028)
9.2 Asia-Pacific Durvalumab Sales by Application (2017-2028)
9.3 Asia-Pacific Durvalumab Market Size by Region
9.3.1 Asia-Pacific Durvalumab Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Durvalumab Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Durvalumab Sales by Type (2017-2028)
10.2 South America Durvalumab Sales by Application (2017-2028)
10.3 South America Durvalumab Market Size by Country
10.3.1 South America Durvalumab Sales in Volume by Country (2017-2028)
10.3.2 South America Durvalumab Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Durvalumab Sales by Type (2017-2028)
11.2 Middle East & Africa Durvalumab Sales by Application (2017-2028)
11.3 Middle East & Africa Durvalumab Market Size by Country
11.3.1 Middle East & Africa Durvalumab Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Durvalumab Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Durvalumab and Key Manufacturers
12.2 Manufacturing Costs Percentage of Durvalumab
12.3 Durvalumab Production Process
12.4 Durvalumab Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Durvalumab Typical Distributors
13.3 Durvalumab Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
List of TablesList of Tables
Table 1. Global Durvalumab Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Durvalumab Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Medimmune (AstraZeneca) Basic Information, Manufacturing Base and Competitors
Table 4. Medimmune (AstraZeneca) Major Business
Table 5. Medimmune (AstraZeneca) Durvalumab Product and Services
Table 6. Medimmune (AstraZeneca) Durvalumab Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Global Durvalumab Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Pcs)
Table 8. Global Durvalumab Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 9. Market Position of Manufacturers in Durvalumab, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 10. Global Durvalumab Production Capacity by Company, (K Pcs): 2020 VS 2021
Table 11. Head Office and Durvalumab Production Site of Key Manufacturer
Table 12. Durvalumab New Entrant and Capacity Expansion Plans
Table 13. Durvalumab Mergers & Acquisitions in the Past Five Years
Table 14. Global Durvalumab Sales by Region (2017-2022) & (K Pcs)
Table 15. Global Durvalumab Sales by Region (2023-2028) & (K Pcs)
Table 16. Global Durvalumab Revenue by Region (2017-2022) & (USD Million)
Table 17. Global Durvalumab Revenue by Region (2023-2028) & (USD Million)
Table 18. Global Durvalumab Sales by Type (2017-2022) & (K Pcs)
Table 19. Global Durvalumab Sales by Type (2023-2028) & (K Pcs)
Table 20. Global Durvalumab Revenue by Type (2017-2022) & (USD Million)
Table 21. Global Durvalumab Revenue by Type (2023-2028) & (USD Million)
Table 22. Global Durvalumab Price by Type (2017-2022) & (USD/Pcs)
Table 23. Global Durvalumab Price by Type (2023-2028) & (USD/Pcs)
Table 24. Global Durvalumab Sales by Application (2017-2022) & (K Pcs)
Table 25. Global Durvalumab Sales by Application (2023-2028) & (K Pcs)
Table 26. Global Durvalumab Revenue by Application (2017-2022) & (USD Million)
Table 27. Global Durvalumab Revenue by Application (2023-2028) & (USD Million)
Table 28. Global Durvalumab Price by Application (2017-2022) & (USD/Pcs)
Table 29. Global Durvalumab Price by Application (2023-2028) & (USD/Pcs)
Table 30. North America Durvalumab Sales by Country (2017-2022) & (K Pcs)
Table 31. North America Durvalumab Sales by Country (2023-2028) & (K Pcs)
Table 32. North America Durvalumab Revenue by Country (2017-2022) & (USD Million)
Table 33. North America Durvalumab Revenue by Country (2023-2028) & (USD Million)
Table 34. North America Durvalumab Sales by Type (2017-2022) & (K Pcs)
Table 35. North America Durvalumab Sales by Type (2023-2028) & (K Pcs)
Table 36. North America Durvalumab Sales by Application (2017-2022) & (K Pcs)
Table 37. North America Durvalumab Sales by Application (2023-2028) & (K Pcs)
Table 38. Europe Durvalumab Sales by Country (2017-2022) & (K Pcs)
Table 39. Europe Durvalumab Sales by Country (2023-2028) & (K Pcs)
Table 40. Europe Durvalumab Revenue by Country (2017-2022) & (USD Million)
Table 41. Europe Durvalumab Revenue by Country (2023-2028) & (USD Million)
Table 42. Europe Durvalumab Sales by Type (2017-2022) & (K Pcs)
Table 43. Europe Durvalumab Sales by Type (2023-2028) & (K Pcs)
Table 44. Europe Durvalumab Sales by Application (2017-2022) & (K Pcs)
Table 45. Europe Durvalumab Sales by Application (2023-2028) & (K Pcs)
Table 46. Asia-Pacific Durvalumab Sales by Region (2017-2022) & (K Pcs)
Table 47. Asia-Pacific Durvalumab Sales by Region (2023-2028) & (K Pcs)
Table 48. Asia-Pacific Durvalumab Revenue by Region (2017-2022) & (USD Million)
Table 49. Asia-Pacific Durvalumab Revenue by Region (2023-2028) & (USD Million)
Table 50. Asia-Pacific Durvalumab Sales by Type (2017-2022) & (K Pcs)
Table 51. Asia-Pacific Durvalumab Sales by Type (2023-2028) & (K Pcs)
Table 52. Asia-Pacific Durvalumab Sales by Application (2017-2022) & (K Pcs)
Table 53. Asia-Pacific Durvalumab Sales by Application (2023-2028) & (K Pcs)
Table 54. South America Durvalumab Sales by Country (2017-2022) & (K Pcs)
Table 55. South America Durvalumab Sales by Country (2023-2028) & (K Pcs)
Table 56. South America Durvalumab Revenue by Country (2017-2022) & (USD Million)
Table 57. South America Durvalumab Revenue by Country (2023-2028) & (USD Million)
Table 58. South America Durvalumab Sales by Type (2017-2022) & (K Pcs)
Table 59. South America Durvalumab Sales by Type (2023-2028) & (K Pcs)
Table 60. South America Durvalumab Sales by Application (2017-2022) & (K Pcs)
Table 61. South America Durvalumab Sales by Application (2023-2028) & (K Pcs)
Table 62. Middle East & Africa Durvalumab Sales by Region (2017-2022) & (K Pcs)
Table 63. Middle East & Africa Durvalumab Sales by Region (2023-2028) & (K Pcs)
Table 64. Middle East & Africa Durvalumab Revenue by Region (2017-2022) & (USD Million)
Table 65. Middle East & Africa Durvalumab Revenue by Region (2023-2028) & (USD Million)
Table 66. Middle East & Africa Durvalumab Sales by Type (2017-2022) & (K Pcs)
Table 67. Middle East & Africa Durvalumab Sales by Type (2023-2028) & (K Pcs)
Table 68. Middle East & Africa Durvalumab Sales by Application (2017-2022) & (K Pcs)
Table 69. Middle East & Africa Durvalumab Sales by Application (2023-2028) & (K Pcs)
Table 70. Durvalumab Raw Material
Table 71. Key Manufacturers of Durvalumab Raw Materials
Table 72. Direct Channel Pros & Cons
Table 73. Indirect Channel Pros & Cons
Table 74. Durvalumab Typical Distributors
Table 75. Durvalumab Typical Customers
List of Figures
Figure 1. Durvalumab Picture
Figure 2. Global Durvalumab Revenue Market Share by Type in 2021
Figure 3. 2.4mL Injection
Figure 4. 10mL Injection
Figure 5. Global Durvalumab Revenue Market Share by Application in 2021
Figure 6. Locally Advanced Urothelial Carcinoma
Figure 7. Metastatic Urothelial Carcinoma
Figure 8. Other
Figure 9. Global Durvalumab Revenue, (USD Million) & (K Pcs): 2017 & 2021 & 2028
Figure 10. Global Durvalumab Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global Durvalumab Sales (2017-2028) & (K Pcs)
Figure 12. Global Durvalumab Price (2017-2028) & (USD/Pcs)
Figure 13. Global Durvalumab Production Capacity (2017-2028) & (K Pcs)
Figure 14. Global Durvalumab Production Capacity by Geographic Region: 2022 VS 2028
Figure 15. Durvalumab Market Drivers
Figure 16. Durvalumab Market Restraints
Figure 17. Durvalumab Market Trends
Figure 18. Global Durvalumab Sales Market Share by Manufacturer in 2021
Figure 19. Global Durvalumab Revenue Market Share by Manufacturer in 2021
Figure 20. Durvalumab Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 21. Top 3 Durvalumab Manufacturer (Revenue) Market Share in 2021
Figure 22. Top 6 Durvalumab Manufacturer (Revenue) Market Share in 2021
Figure 23. Global Durvalumab Sales Market Share by Region (2017-2028)
Figure 24. Global Durvalumab Revenue Market Share by Region (2017-2028)
Figure 25. North America Durvalumab Revenue (2017-2028) & (USD Million)
Figure 26. Europe Durvalumab Revenue (2017-2028) & (USD Million)
Figure 27. Asia-Pacific Durvalumab Revenue (2017-2028) & (USD Million)
Figure 28. South America Durvalumab Revenue (2017-2028) & (USD Million)
Figure 29. Middle East & Africa Durvalumab Revenue (2017-2028) & (USD Million)
Figure 30. Global Durvalumab Sales Market Share by Type (2017-2028)
Figure 31. Global Durvalumab Revenue Market Share by Type (2017-2028)
Figure 32. Global Durvalumab Price by Type (2017-2028) & (USD/Pcs)
Figure 33. Global Durvalumab Sales Market Share by Application (2017-2028)
Figure 34. Global Durvalumab Revenue Market Share by Application (2017-2028)
Figure 35. Global Durvalumab Price by Application (2017-2028) & (USD/Pcs)
Figure 36. North America Durvalumab Sales Market Share by Type (2017-2028)
Figure 37. North America Durvalumab Sales Market Share by Application (2017-2028)
Figure 38. North America Durvalumab Sales Market Share by Country (2017-2028)
Figure 39. North America Durvalumab Revenue Market Share by Country (2017-2028)
Figure 40. United States Durvalumab Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Canada Durvalumab Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Mexico Durvalumab Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Europe Durvalumab Sales Market Share by Type (2017-2028)
Figure 44. Europe Durvalumab Sales Market Share by Application (2017-2028)
Figure 45. Europe Durvalumab Sales Market Share by Country (2017-2028)
Figure 46. Europe Durvalumab Revenue Market Share by Country (2017-2028)
Figure 47. Germany Durvalumab Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. France Durvalumab Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. United Kingdom Durvalumab Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Russia Durvalumab Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Italy Durvalumab Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Asia-Pacific Durvalumab Sales Market Share by Region (2017-2028)
Figure 53. Asia-Pacific Durvalumab Sales Market Share by Application (2017-2028)
Figure 54. Asia-Pacific Durvalumab Sales Market Share by Region (2017-2028)
Figure 55. Asia-Pacific Durvalumab Revenue Market Share by Region (2017-2028)
Figure 56. China Durvalumab Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Japan Durvalumab Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Korea Durvalumab Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. India Durvalumab Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Southeast Asia Durvalumab Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Australia Durvalumab Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. South America Durvalumab Sales Market Share by Type (2017-2028)
Figure 63. South America Durvalumab Sales Market Share by Application (2017-2028)
Figure 64. South America Durvalumab Sales Market Share by Country (2017-2028)
Figure 65. South America Durvalumab Revenue Market Share by Country (2017-2028)
Figure 66. Brazil Durvalumab Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Argentina Durvalumab Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Middle East & Africa Durvalumab Sales Market Share by Type (2017-2028)
Figure 69. Middle East & Africa Durvalumab Sales Market Share by Application (2017-2028)
Figure 70. Middle East & Africa Durvalumab Sales Market Share by Region (2017-2028)
Figure 71. Middle East & Africa Durvalumab Revenue Market Share by Region (2017-2028)
Figure 72. Turkey Durvalumab Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Egypt Durvalumab Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Saudi Arabia Durvalumab Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. South Africa Durvalumab Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Manufacturing Cost Structure Analysis of Durvalumab in 2021
Figure 77. Manufacturing Process Analysis of Durvalumab
Figure 78. Durvalumab Industrial Chain
Figure 79. Sales Channel: Direct Channel vs Indirect Channel
Figure 80. Methodology
Figure 81. Research Process and Data Source
Published By : GlobalInfoResearch
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
